TAZVERIK (tazemetostat)
TherapyIpsen
TAZVERIK (tazemetostat) from Ipsen is an EZH2 inhibitor used in epithelioid sarcoma and follicular lymphoma with EZH2 alterations.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TAZVERIK. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where TAZVERIK is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Follicular Lymphoma Tumor Heme · Lymphoma | EZH2
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TAZVERIK.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TAZVERIK for eligible patients.
Test
cobas EZH2 Mutation Test
Roche Molecular Systems, Inc. (Roche Diagnostics)
Method
PCR
Specimen
Tissue (FFPE)
1 approvalView test profile →